Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine

(2019) Peter J Goadsby et al.   BRAIN

Migraine is first cause of disability in under 50s: will health politicians now take notice?

(2018) Timothy J. Steiner et al.   JOURNAL OF HEADACHE AND PAIN

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation

(2018) Lars Bendtsen et al.   JOURNAL OF HEADACHE AND PAIN

Lasmiditan is an effective acute treatment for migraine

(2018) Bernice Kuca et al.   NEUROLOGY

Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

(2017) Theo Vos et al.   LANCET

Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache

(2016) David M. Simpson et al.   NEUROLOGY

A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study

(2013) Lars J Stovner et al.   CEPHALALGIA

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Table 1

(2012) S.D. Silberstein et al.   NEUROLOGY

Rizatriptan for Treatment of Acute Migraine in Patients Taking Topiramate for Migraine Prophylaxis

(2011) Jeffrey L. Seeburger et al.   HEADACHE

Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan

(2010) David L Nelson et al.   CEPHALALGIA

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

(2010) SK Aurora et al.   CEPHALALGIA

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

(2010) HC Diener et al.   CEPHALALGIA

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program

(2010) David W. Dodick et al.   HEADACHE

EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force

(2009) S. Evers et al.   EUROPEAN JOURNAL OF NEUROLOGY